Beyond ADCs: harnessing bispecific antibodies to directly induce apoptosis for targeted tumor eradication [0.03%]
超越ADCs：利用双特异性抗体直接诱导凋亡进行肿瘤的靶向根除
Victor S Goldmacher,Iosif M Gershteyn,Yelena Kovtun
Victor S Goldmacher
Bispecific apoptosis triggers (BATs) are innovative bispecific antibodies designed to simultaneously target both a tumor-associated antigen and a cancer cell's death receptor, thereby directly activating the extrinsic apoptotic pathway to i...
Current use and development of monoclonal antibodies for the treatment of systemic lupus erythematosus: a review [0.03%]
单克隆抗体治疗系统性红斑狼疮的现状与开发进展：综述
Alexander Blagov,Nikolay Orekhov,Alexey Churov et al.
Alexander Blagov et al.
The development of targeted drugs for the treatment of systemic lupus erythematosus (SLE) is a promising area of research because targeted drugs are associated with a lower risk of severe side effects than systemic drugs. There are only two...
Near-infrared photoimmunotherapy: mechanisms, applications, and future perspectives in cancer research [0.03%]
近红外光免疫疗法：癌症研究中的机制、应用及未来展望
Derek Allen,Madeline JoAnna Szoo,Tessa D van Bergen et al.
Derek Allen et al.
Photoimmunotherapy (PIT) involves the targeted delivery of a photosensitizer through antibody conjugation, which, upon binding to its cellular target and activation by external irradiation, induces localized toxicity. This approach addresse...
Generation of antagonistic biparatopic anti-CD30 antibody from an agonistic antibody by precise epitope determination and utilization of structural characteristics of CD30 molecule [0.03%]
通过精确表位测定和利用CD30分子的结构特征从激动抗体生成抗对立双特异性抗CD30抗体
Hiroki Akiba,Tomoko Ise,Reiko Satoh et al.
Hiroki Akiba et al.
Background: CD30 is a member of the tumor necrosis factor receptor superfamily. Recently, blocking CD30-dependent intracellular signaling has emerged as potential strategy for immunological regulation. Development of anti...
Discovery of a common light chain bispecific antibody targeting PD-1 and PD-L1 by Hybridoma-to-Phage-to-Yeast (H2PtY) platform [0.03%]
利用杂交瘤到噬菌体到酵母平台筛选得到的靶向PD-1和PD-L1的通用型轻链双特异性抗体
Peipei Liu,Chunyin Gu,Xiaodan Cao et al.
Peipei Liu et al.
Background: Therapeutic antibody drugs targeting the PD-1 pathway are generally characterized by relatively low response rates and susceptibility to drug resistance during clinical application. Therefore, there is an urge...
Yuan Cheng,Huu Thuy Trang Duong,Qingyan Hu et al.
Yuan Cheng et al.
The development of lyophilized protein drug products is a critical and complex task in the pharmaceutical industry, requiring a comprehensive understanding of the myriad of factors affecting product quality, stability, and the efficiency an...
Humanized anti-CD11d monoclonal antibodies suitable for basic research and therapeutic applications [0.03%]
适合基础研究和治疗应用的人源化抗CD11d单克隆抗体
Eoin N Blythe,Christy Barreira,Corby Fink et al.
Eoin N Blythe et al.
Background: Immunomodulatory agents targeting the CD11d/CD18 integrin are in development for the treatment of several pathophysiologies including neurotrauma, sepsis, and atherosclerosis. Murine anti-human CD11d therapeut...
A bioluminescent reporter bioassay for in-process assessment of chimeric antigen receptor lentiviral vector potency [0.03%]
一种用于嵌合抗原受体慢病毒载体功效的工艺评估的生物发光报告基因检测方法
Julia K Gilden,Pete Stecha,Jim Hartnett et al.
Julia K Gilden et al.
Background: Chimeric antigen receptor (CAR)-T-cell therapy is a breakthrough in the field of cancer immunotherapy, wherein T cells are genetically modified to recognize and attack cancer cells. Delivery of the CAR gene is...
Directed protein engineering identifies a human TIM-4 blocking antibody that enhances anti-tumor response to checkpoint inhibition in murine colon carcinoma [0.03%]
导向性蛋白质工程鉴定出一种人TIM-4阻断型抗体，可增强小鼠结肠癌中检点抑制的抗肿瘤反应
Karla K Frietze,Kamala Anumukonda,Laura Padula et al.
Karla K Frietze et al.
Background: T-cell immunoglobulin and mucin domain containing molecule-4 (TIM-4) is a scavenger receptor best known for its role in recognizing dying cells. TIM-4 orchestrates phagocytosis allowing for cellular clearance ...
Leveraging high-throughput analytics and automation to rapidly develop high-concentration mAb formulations: integrated excipient compatibility and viscosity screening [0.03%]
利用高通量分析和自动化技术快速开发高浓度单克隆抗体制剂：集成了辅料相容性和粘度筛选
Lun Xin,Lan Lan,Mourad Mellal et al.
Lun Xin et al.
Background: Formulation screening is essential to experimentally balance stability and viscosity in high-concentration mAb formulations. We developed a high-throughput approach with automated sample preparation and analyt...